All Posts Tagged With: "CNS"
(ALNY) Alnylam States Preclinical Data
Alnylam Pharmaceuticals Inc (ALNY) recently announced pre-clinical data from a trial evaluating its pipeline candidate ALN-HTT for the treatment of Huntington’s disease (HD). ALN-HTT is a novel therapeutic...
(THRX) Theravance Third Quarter Loss Deteriorates
Theravance Inc.’s (THRX) third quarter 2011 loss per share of 37 cents was wider than the Zacks Consensus loss Estimate of 33 cents as well as the year-ago loss of 29 cents per share. The wider loss was...
(AAPL) A Busy Week Ahead – Earnings Preview
Earnings Preview 10/14/11
While the earnings season kicked off this past week, only 38 firms reported. The game really gets under way next week, when we will get reports from 336 firms, including 99 members of the S&P 500.
Thus, by the end of the week we...
(ALKS) Alkermes Analyst Maintains Neutral Rating on Shares
We are maintaining our Neutral recommendation on Alkermes, Inc. (ALKS). Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop drugs for the...
(AAPL) 2011 Second Quarter Earnings Preview – Detailed
Earnings Preview 7/15/11
Second quarter earnings season is now under way, but things really start to move into high gear next week. There will be 348 firms reporting, and 108 of those are...
(ALKS) Alkermes Evenly Poised
We are maintaining our Neutral recommendation on Alkermes, Inc. (ALKS) with a target price of $18.00.
Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery...
(CEPH) Cephalon First Quarter 2011 Earnings Miss Expectations
Cephalon Inc. (CEPH) delivered first quarter earnings of $1.98 per share, several cents below the Zacks Consensus Estimate of $2.04 but 12.5% above the year-ago earnings of $1.76.
First quarter revenues,...
(MRK) Five Large Cap Pharmaceuticals to Consider
The Large Cap Pharma sector is the fastest rising sector on Barchart when screening for the 1 month price change. The general investing public is very interested in this sector as evidenced by the 25,409 opinions expressed on Motley Fool on the 5 stocks I selected. Before...
(CYPB) Cypress Bioscience Reports Wider Loss
Cypress Bioscience, Inc. (CYPB) reported a net loss of 94 cents per share in the third quarter, significantly higher than the Zacks Consensus Estimate of a loss of 33 cents and the year ago loss of 12 cents....
(CEPH) Cephalon Reports Very Strong Quarterly Earnings
Cephalon, Inc. (CEPH) delivered another strong quarter with earnings coming at $2.14 per share, easily beating the Zacks Consensus Estimate of $1.79 and well above the year-ago earnings of $1.62.
Strong...
(CYPB) Cypress Bioscience Signs Deal With Marina Biotech
Recently, Cypress Bioscience, Inc. (CYPB) announced that it has inked a deal with Marina Biotech, Inc. (MRNA). The deal, which allows Cypress...
(CYTX) U.S. Government Stem Cell Policy Confusion Creates Opportunity
On Monday, August 23, 2010, the Federal District Court for the District of Columbia issued a temporary injunction on President Obama’s 2009 executive order that expanded federal funding for embryonic stem cell research, returning to order the previous ban enforced by the...
(CEPH) Cephalon Files Lawsuit Against Apotex – Several Companies Challenging Nuvigil Patent
In a recent filing with the US Securities and Exchange Commission (SEC), Cephalon Inc. (CEPH) announced that it has filed a lawsuit in the US District Court in Delaware against Apotex Corp. and Apotex Inc....
(CEPH) Cephalon Second Quarter 2010 Earnings Report Beats The Street
Cephalon Inc. (CEPH) delivered another strong quarter with second quarter earnings coming in at $2.05 per share, six cents above the Zacks Consensus Estimate and well above the year-ago earnings of $1.44...
(CEPH) Cephalon Second Quarter 2010 Earnings Preview
Cephalon Inc. (CEPH) is scheduled to report second quarter results on July 27, 2010 after the market closes. The current Zacks Consensus Estimate for the second quarter is $1.99 per diluted share, representing...
(CEPH) Cephalon’s Quarterly Earnings Report Beats – Updates Guidance
Cephalon, Inc. (CEPH) started 2010 on a strong note with first quarter earnings beating expectations by a wide margin. The company reported first quarter earnings of $1.76 per share, 20 cents above the Zacks...
(CEPH) Cephalon Earnings Estimates Up on Company Guidance
Earnings estimates for Cephalon, Inc. (CEPH) have gone up significantly following the issuance of a better-than-expected guidance by the company. Cephalon exited 2009 on a strong note with both fourth-quarter...
(CEPH) Cephalon Beats Earnings Expectations and Guides Higher
Cephalon, Inc. (CEPH) exited 2009 on a strong note with both fourth quarter and full year earnings exceeding expectations. The company reported fourth quarter earnings of $1.66 per share, 6 cents above the...
(ALKS) Alkermes Retains Neutral Recommendation
We maintain our Neutral rating on Alkermes, Inc. (ALKS) with a price target of $11.50.
Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies...
(CNS) Overvalued Stocks: Don’t Touch These Bloated Investments With a 10-Foot Pole
by Marc Lichtenfeld, Healthcare Expert
Wednesday, November 18, 2009: Issue...
($CEPH) Cephalon Beats Forecasts – Provides Outlook
Cephalon Inc. (CEPH) reported strong third-quarter earnings of $1.62 per share that easily surpassed the Zacks Consensus Estimate of $1.42 per share and the year ago earnings of $1.18. Revenues increased...
(SEPR) Dainippon-Sepracor Deal Emerges
Today, Dainippon Sumitomo and Sepracor (SEPR) have announced the successful completion of the initial share offering period, where almost 78.2% of Sepracor’s shares were tendered. The offer period has been extended to Oct 19, 2009, to enable other shareholders...
(SEPR) Dainippon Sumitomo Pharma Acquires Sepracor
Today morning, Japanese pharmaceutical company Dainippon Sumitomo Pharma Co., Ltd. confirmed that it signed a definitive agreement to buy U.S. pharmaceutical company Sepracor Inc. (SEPR). The deal has been valued at $23 per share or $2.6 billion.